ENANTA PHARMACEUTICALS, INC
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.4M | $17.2M | $18.6M | $15.1M | $18.3M | $14.9M | $17.0M | $14.6M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $22.1M | $19.4M | $20.9M | $23.8M | $27.2M | $28.1M | $27.7M | $30.8M |
| SG&A Expense | $9.5M | $9.6M | $9.0M | $9.7M | $10.0M | $11.4M | $12.8M | $13.7M |
| Operating Income | $-17.2M | $-11.9M | $-11.3M | $-18.4M | $-18.9M | $-24.5M | $-23.5M | $-29.9M |
| Operating Margin | -120.0% | -69.1% | -60.5% | -121.6% | -103.2% | -164.3% | -138.8% | -204.4% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-19.5M | $-13.1M | $-11.9M | $-18.7M | $-18.2M | $-23.9M | $-22.7M | $-29.2M |
| Income Tax Expense | $36.0K | $7.0K | $24.0K | $32.0K | $29.0K | $-1.3M | $-416.0K | $-363.0K |
| Net Income | $-19.5M | $-13.1M | $-11.9M | $-18.7M | $-18.3M | $-22.6M | $-22.3M | $-28.8M |
| Net Margin | -135.8% | -76.3% | -64.1% | -123.6% | -99.7% | -151.7% | -131.4% | -197.3% |
| EPS (Basic) | $-0.67 | $-0.45 | $-0.42 | $-0.88 | $-0.85 | $-1.06 | $-1.05 | $-1.36 |
| EPS (Diluted) | $-0.67 | $-0.45 | $-0.42 | $-0.88 | $-0.85 | $-1.06 | $-1.05 | $-1.36 |
| Shares Outstanding (Basic) | 29.1M | 29.0M | 28.7M | 21.3K | 21.4M | 21.4M | 21.2M | 21.2K |
| Shares Outstanding (Diluted) | 29.1M | 29.0M | 28.7M | 21.3K | 21.4M | 21.4M | 21.2M | 21.2K |
| Dividends Per Share | — | — | — | — | — | — | — | — |